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Abstract
Background: Avian metapneumoviruses (aMPV) cause an upper respiratory disease with low
mortality, but high morbidity primarily in commercial turkeys. There are three types of aMPV (A,
B, C) of which the C type is found only in the United States. Viruses related to aMPV include human,
bovine, ovine, and caprine respiratory syncytial viruses and pneumonia virus of mice, as well as the
recently identified human metapneumovirus (hMPV). The aMPV and hMPV have become the type
viruses of a new genus within the Metapneumovirus. The aMPV nucleoprotein (N) amino acid
sequences of serotypes A, B, and C were aligned for comparative analysis. Based on predicted
antigenicity of consensus protein sequences, five aMPV-specific N peptides were synthesized for
development of peptide-antigens and antisera.
Results: The presence of two aMPV nucleoprotein (N) gene encoded polypeptides was detected
in aMPV/C/US/Co and aMPV/A/UK/3b infected Vero cells. Nucleoprotein 1 (N1) encoded from the
first open reading frame (ORF) was predicted to be 394 amino acids in length for aMPV/C/US/Co
and 391 amino acids in length for aMPV/A/UK/3b with approximate molecular weights of 43.3
kilodaltons and 42.7 kilodaltons, respectively. Nucleoprotein 2 (N2) was hypothesized to be
encoded by a second downstream ORF in-frame with ORF1 and encoded a protein predicted to
contain 328 amino acids for aMPV/C/US/Co or 259 amino acids for aMPV/A/UK/3b with
approximate molecular weights of 36 kilodaltons and 28.3 kilodaltons, respectively. Peptide
antibodies to the N-terminal and C-terminal portions of the aMPV N protein confirmed presence
of these products in both aMPV/C/US/Co- and aMPV/A/UK/3b-infected Vero cells. N1 and N2 for
aMPV/C/US/Co ORFs were molecularly cloned and expressed in Vero cells utilizing eukaryotic
expression vectors to confirm identity of the aMPV encoded proteins.
Conclusion: This is the first reported identification of potential, accessory in-frame N2 ORF gene
products among members of the Paramyxoviridae. Genomic sequence analyses of related members
of the Pneumovirinae other than aMPV, including human respiratory syncytial virus and bovine
respiratory syncytial virus demonstrated the presence of this second potential ORF among these
agents.
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Background
Avian metapneumovirus (aMPV) causes turkey rhinotra-
cheitis (TRT) and is associated with swollen head syn-
drome (SHS) of chickens that is usually accompanied by
secondary bacterial infections which can increase morbid-
ity and induce mortality. Avian metpnuemovirus was first
reported in South Africa during the early 1970s and was
subsequently isolated in Europe, Israel and Asia [1,2].
During 1997, mortality due to aMPV infections among
commercial turkeys in the U.S. ranged from zero, to 30%
when accompanied by bacterial infections, with condem-
nations due to air sacculitis. This was the first reported
outbreak of aMPV infections in the U.S. which was previ-
ously considered exotic to North America. The virus caus-
ing disease was designated a new aMPV type C genetically
different from European counterparts [3-5] and was sub-
sequently demonstrated to be most closely related to
human metapneumovirus (hMPV) from diverse geo-
graphic locations [6,7]. Infections among commercial tur-
keys with aMPV/C continue in the north-central U.S.
resulting in substantial economic loss to the poultry
industry [6,8,9].
Pneumoviruses are members of the family Paramyxoviri-
dae  that contain a nonsegmented, negative-sense RNA
genome of approximately 15 kb in length. Viruses related
to aMPV include human, bovine, ovine and caprine respi-
ratory syncytial viruses and pneumonia virus of mice [10],
as well as the recently identified hMPV [11]. Although
genome length is similar, pneumoviruses generally
encode ten genes, compared to six or seven in other para-
myxoviruses. These include the nonstructural proteins
(NS1 and NS2), nucleoprotein (N), phosphoprotein (P),
matrix protein (M), small hydrophobic protein (SH), sur-
face glycoprotein (G), fusion protein (F), second matrix
protein (M2) and a viral RNA-dependent RNA polymerase
(L). The pneumoviruses have an F protein that promotes
cell fusion, but these viruses do not hemagglutinate, nor
do they have neuraminidase activity in their G attachment
protein. This is an important distinguishing characteristic
from the other paramyxoviruses [10].
Because of a limited genome size, many non-segmented
RNA viruses, including the pneumoviruses, have devised
mechanism to increase protein coding capacities. This
may occur at two levels: 1) transcriptional mRNA process-
ing or modification [12-14] or 2) translational, in which
proteins may be produced from alternative open reading
frames (ORFs) or from translational initiation at non-
AUG or downstream AUG codons [15-17]. Among the
pneumoviruses, secondary coding usage has only been
documented for the M2 gene, which encodes two pro-
teins. The M2-1, a transcription antitermination factor, is
required for processive RNA synthesis and transcription
read-through at gene junctions. The M2-2 is involved with
the shift between viral RNA transcription and replication
[18]. In this report, we present evidence for utilization of
a secondary open reading frame, within the N gene encod-
ing a truncated nucleoprotein (N2) among aMPV/C/Co
and aMPV/A/UK/3b infected cells.
Results
Avian metapneumovirus N gene possess several putative 
AUG start sites
The aMPV/C/US/Co nucleoprotein is encoded by the N
gene with a predicted molecular weight of 42–45 kD
[7,19]. The N gene ranges from 1191 to 1206 nucleotides
in length [6,19], with the first AUG at nucleotide position
14 (Fig. 1) in all three subtypes (A, B, and C). The aMPV/
C/US/Co N gene has additional putative start sites at
nucleotide positions 212, 350, 416, 758, 785, 827, 896,
and 1022 with "true" Kozak sequences [20] at nucleotide
positions 413 (ACCAUGG) and 893 (GAGAUGG), with
predicted translation products of 28.5 kD and 10.78 kD,
respectively. The aMPV/A/UK/3b N gene has additional
putative start sites at nucleotide positions 161, 212, 293,
410, 413, 605, 722, 749, 749, 776, 818, 887, and 1013
with "true" Kozak sequences [20] at nucleotide positions
602 (AGGAUGG), 719 (AGGAUGG), and 884
(AAAAUGG), with predicted translation products of
21.26 kD, 16.73 kD, and 10.54 kD, respectively.
Avian metapneumovirus-infected cells produce two 
proteins (N1 and N2) encoded by two open-reading frames 
within the N gene
Five peptides within the aMPV N gene (Fig. 2) were uti-
lized to generate affinity-purified rabbit peptide antibod-
ies. This approach was exploited to determine if any of the
alternative start sites of the aMPV N gene were utilized
during an active cell infection. aMPV/N-peptide antibody
directed against aMPV/C/US/Co N protein amino acids
10–29 (DLSYKHAILKESQYTIKRDV) with only 3 changes
in both aMPV types A and B at amino acid positions 12 (S
to E), 19 (K to D) and 26 (K to R) reacted with all three
full length nucleoproteins by western blot (Fig. 3A, Lanes
3, 4, and 5), but did not react with any proteins in unin-
fected Vero cells (Fig. 3A, Lane 2). All three virus nucleo-
proteins were between 42–45 kD based on SDS-PAGE/
western blot analysis (Fig. 3A). We then tested the aMPV/
C-N2 peptide antibody directed against amino acids 128–
148 in the mid-portion of the of the aMPV/C/US/Co iso-
late (Fig. 2) by western blot which would recognize any
downstream translation products encoded by the N gene
and utilization of any secondary start sites. Western blot
analysis revealed two putative N gene products in aMPV/
C/US/Co-infected Vero cells, the first, the full-length
nucleoprotein with a molecular weight of approximately
43 kD (Fig. 3B, Lane 3) and the second, a smaller protein
of approximately 35–36 kD (Fig. 3B, Lane 3). The peptide
antibody to amino acids 303 to 393 (aMPV/C-N4)Virology Journal 2005, 2:31 http://www.virologyj.com/content/2/1/31
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synthesized to be reactive to the C-terminal N protein
from aMPV/C also recognized two proteins as in Fig. 3B,
Lane 3 (data not shown).
To evaluate whether the utilization of alternative start sites
was unique to members of the aMPV type C group, or
whether this also occurred in other aMPV types, we uti-
lized aMPV/A-N3 and aMPV/A-N5 peptide antibodies
(anti-aMPV/Type A, N protein, amino acids 126–145 and
380–390, respectively). Unlike aMPV/C-N2 peptide anti-
body, aMPV/A-N3-peptide antibody (amino acids 126–
145) reacted to only a full length nucleoprotein (Fig. 3C,
lane 3) similar to the aMPV/N-peptide antibody (Fig. 3C,
lane 2), while aMPV/A-N5-peptide antibody (amino acids
380–390) reacted with both the full length nucleoprotein
of approximately 41–43 kD (Fig. 3C, lane 4) and a smaller
protein of approximately 28–30 kD (Fig. 3C, lane 4).
Finally, all aMPV type-specific antibodies were not cross
active with other metapneumoviruses (data not shown).
Expression of the N1 and N2 ORF of avian 
metapneumovirus type C/Colorado in eukaryotic cells
Sequence analysis of the aMPV/C/US/Co and aMPV/A/
UK/3b N gene nucleotide sequences revealed that down-
stream of the first AUG (position 14) were multiple puta-
tive start sites as described above (Fig. 1). We therefore
utilized sequence analysis software to analyze the N gene
putative open reading frames and the predicted transla-
tion products from each putative start site for products
that would result in proteins of approximate size as the
smaller reactive band that was detected by western blot
(Fig. 3B, lane 3 and Fig. 3C, lane 4). Two predicted pro-
teins in the aMPV/C/US/Co sequences corresponding to a
predicted molecular weight of approximately 31.12 kD
Alignment of avian metapneumovirus type A and C nucleoprotein genes demonstrating presence of multiple start sites Figure 1
Alignment of avian metapneumovirus type A and C nucleoprotein genes demonstrating presence of multiple start sites. Under-
lined sequences denote hypothesized alternative in-frame start sites and the stop codon. Primer sequences utilized for cDNA 
synthesis of nucleoprotein genes are also illustrated.
                  N1 ______________________________
aMPV/C/US/Co  GGGACAAGTG AAAATGTCTC TTCAGGGGAT TCAGCTTAGT GACTTGTCCT ATAAGCATGC AATCCTTAAA GAATCACAGT ACACAATCAA    90
aMPV/A/UK/3b  GGGACAAGTC AAAATGTCTC TTGAAAGTAT TAGACTCAGT GACTTGGAGT ACAAACATGC AATTCTTGAA GACTCTCAGT ATACAATTAG    90
aMPV/C/US/Co  AAGAGATGTG GGGACAACCA CAGCTGTCAC TCCGTCTTCT CTGCAGAGGG AAGTGTCACT CTTATGTGGA GAGATACTGT ATGCCAAGCA   180
aMPV/A/UK/3b  AAGGGATGTT GGTGCTACCA CTGCGATCAC ACCTTCCGAA CTGCAGCCGC AAGTATCCAC ATTATGCGGT ATGGTGTTGT TTGCAAAACA   180
                                           N212 ____________________
aMPV/C/US/Co  CACAGATTAC TCACATGCAG CTGAAGTAGG AATGCAGTAC GTGAGCACCA CACTGGGAGC AGAGCGTACA CAGCAGATAC TAAAGAACTC   270
aMPV/A/UK/3b  CACCGACTAT GAGCCTGCAG CAGAGGTAGG CATGCAGTAC ATTAGTACTG CTCTAGGAGC TGATAGAACT CAACAAATAC TGAAAAATTC   270
aMPV/C/US/Co  AGGTAGTGAG GTGCAGGCAG TATTGACCAA GACA--TACT CTCTTGG-GA AGGGCAAAAA CAGCAAAGGG GAGGAGTTGC AAATGTTAGA   357
aMPV/A/UK/3b  CGGTAGTGAA GTACAGGGTG TTATGACCAA GATTGTTACA CTTTCGGCAG AGGGTTCTGT CAGAAAGCGA GAGGTGCT-- AAACATTCAC   358
aMPV/C/US/Co  CATACATGGG GTTGAAAGAA GT--TGG-AT TGAAGAAGTT GACAAAGAGG CAAGGAAAAC CATGGCCTCA GCTACAAAGG ACAACTCAGG   444
aMPV/A/UK/3b  GATGTA-GGT GTTGGGTGGG CTGATGATGT CGAAAGGACT ACAAGAGAAG CAATGGGAGC AATGG--TTA GGGAAAAAGT GCAACTCA--   443
aMPV/C/US/Co  ACCAATACCA CAAAATCAAA GACCATCATC CCCGGATGCT CCTATCATAC TACTCTGCAT AGGAGCATTA ATCTTCACGA AGCTGGCATC   534
aMPV/A/UK/3b  --CAA----- -AGAATCAAA AGCCGTCTGC CTTGGATGCT CCCGTTATTC TATTATGCAT TGGTGCCCTC ATTTTCACCA AGTTGGCCTC   525
aMPV/C/US/Co  AACAATCGAA GTTGGGCTGG AGACAGCTGT TAGAAGGGCA AACCGTGTGC TGAATGATGC ATTGAAAAGG TTCCCAAGGA TTGACATCCC   624
aMPV/A/UK/3b  AACTGTTGAA GTAGGCCTTG AAACTGCTAT CCGGCGTGCC TCAAGGGTAT TAAGCGATGC CATATCACGG TACCCCAGGA TGGACATACC   615
aMPV/C/US/Co  CAAAATTGCG AGGTCCTTTT ATGATCTGTT TGAGCAGAAA GTTTACTACA GGAGCTTGTT TATAGAGTAT GGCAAAGCCC TTGGGTCTTC   714
aMPV/A/UK/3b  AAGGATTGCC AAATCATTCT TTGAATTGTT TGAGAAGAAG GTGTATTACA GAAATCTATT TATTGAATAC GGTAAGGCAC TCGGAAGTAC   705
aMPV/C/US/Co  TTCCACAGGA AGCAAGGCAG AAAGCCTGTT TGTGAATATT TTCATGCAAG CTTATGGTGC AGGTCAGACA ATGCTAAGAT GGGGGGTAAT   804
aMPV/A/UK/3b  ATCCACCGGA AGCAGGATGG AGAGCCTGTT TGTGAATATT TTTATGCAAG CTTATGGGGC AGGGCAAACA ATGCTGCGCT GGGGTGTCAT   795
aMPV/C/US/Co  TGCCAGATCA TCCAACAATA TAATGTTGGG CCATGTCTCC GTACAAGCAG AACTCAAACA GGTTACGGAG GTATATGATC TAGTTAGAGA   894
aMPV/A/UK/3b  TGCACGATCC TCCAACAATA TAATGTTGGG CCATGTATCT GTCCAAGCTG AGTTGAGGCA AGTATCTGAG GTCTATGACC TAGTGAGGAA   885
aMPV/C/US/Co  GATGGGCCCT GAGTCAGGTC TTCTTCACCT GAGGCAAAAC CCTAAGGCAG GGTTGTTGTC ACTTGCCAAT TGTCCCAATT TTGCAAGTGT   984
aMPV/A/UK/3b  AATGGGACCT GAGTCAGGGT TACTACACTT ACGCCAGAGT CCCAAAGCGG GTCTTTTATC ATTGACCAAC TGTCCCAATT TTGCCAGTGT   975
aMPV/C/US/Co  GGTGCTAGGG AATGCCTCAG GATTGGGGAT ACTTGGTATG TACAGAGGAA GAGTACCAAA TACAGAGCTA TTTGCCGCAG CAGAAAGCTA  1074
aMPV/A/UK/3b  TGTCCTCGGG AACGCCGCCG GGCTTGGTAT TATAGGCATG TACAAAGGTC GAGCCCCCAA CCTTGAGCTG TTTGCTGCTG CTGAAAGTTA  1065
aMPV/C/US/Co  TGCAAGAAGC CTAAAAGAAA GCAATAAGAT AAATTTCTCA TCTCTTGGTC TGACAGAAGA GGAAAAAGAA GCTGCTGAGA ACTTTCTCAA  1164
aMPV/A/UK/3b  TGCACGGACA TTGAGAGAGA ACAACAAGAT CAACCTAGCG GCCTTAGGGC TCACTGATGA TGAGAGGGAA GCAGC-AACA TCCTACCTAG  1154
                    _____________________________________ N1185c
aMPV/C/US/Co  CATAA-ATGA -GGAAGGCCA GAATGATTAT GAGTAATTAA AAAA                                             1206
aMPV/A/UK/3b  GGGGAGATGA TGAGAGATCA TCCAAATT-T GAGTAATTAA AAAA                                             1197Virology Journal 2005, 2:31 http://www.virologyj.com/content/2/1/31
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(third AUG) and another at 28.5 kD (fourth AUG) were
detected in the N gene sequence.
Since SDS-PAGE analysis is not necessarily an accurate
measurement of molecular size, both starts sites could
result in a protein observed at approximately 35–36 kD by
SDS-PAGE, and therefore either site could result in the
second ORF product. We therefore used two primer sets
N1/N1189C and N212/N1189C which spans either the
full length of ORF1 or the ORF2 and any down stream
putative ORFs of aMPV/C/US/Co, respectively (Fig. 2) to
amplify both ORFs by RT-PCR. Both ORFs were amplified
and cloned into a eukaryotic expression vector. Western
blot analysis of the Vero cell expressed N1 and N2 ORFs
revealed one reactive band in the pCR3.1-N1ORF trans-
fected Vero cells with the aMPV/N antibody (Fig. 4, lane
4) corresponding to the full length nucleoprotein of
aMPV, similar to that observed in aMPV-infected Vero
cells (Fig. 4, lane 3). This protein was not visualized in the
pCR3.1-N2ORF transfected Vero cells (Fig. 4, lane 5), as
was expected since the N212 primer is downstream of the
peptide (aMPV/N, amino acids, 10–29) utilized to synthe-
size aMPV/N peptide antibody. However, when the
aMPV/C-N2 (peptide antibody directed to amino acids
383–393 of aMPV/C N protein) was used for western blot
analysis, two proteins were reactive in the pCR3.1-N1ORF
Vero cells, the first at approximately 43 kD (Fig. 4, lane 8),
similar to that observed in aMPV-infected Vero cells (Fig.
4, Lane 7) and the second, a protein of approximately 35
kD (Fig. 4, Lane 8), slightly smaller than the N2 ORF pro-
tein in aMPV-infected Vero cells (Fig. 4, Lane 7). Western
blot analysis of the pCR3.1-N2ORF induced Vero cells
demonstrated one reactive band of approximately 35 kD
(Fig. 4, Lane 9), similar to the smaller reactive band in the
pCR3.1-N1ORF transfected Vero cells. The full-length
nucleoprotein, as expected was not present in the pCR3.1-
N2ORF transfected Vero cells, since the N212 primer is
downstream of the first AUG start site (position 14).
Discussion
The utilization of alternative open reading frames for the
expansion of genetic information in negative-stranded
RNA viruses has been well documented [10,16,17,21,22].
There are, however, various mechanisms for accessing this
genetic information. The phosphoprotein of measles virus
encodes a single mRNA, which is read in two
Relative position of peptides within the avian metapneumovirus nucleoproteins utilized for generation of affinity purified poly- clonal antibodies Figure 2
Relative position of peptides within the avian metapneumovirus nucleoproteins utilized for generation of affinity purified poly-
clonal antibodies.
aMPV/C Nucleoprotein (N)
NH2- COOH
14-1196 350-1196
ORF 1  ORF 2
Peptide 1 – anti-aMPV Peptide 2 – anti-aMPV/C
Peptide 3 – anti-aMPV/A
Peptide 4 – anti-aMPV/C
Peptide 5 – anti-aMPV/A
N1 ORF
N2 ORF
43.3 kD
31 kDVirology Journal 2005, 2:31 http://www.virologyj.com/content/2/1/31
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independently initiated overlapping reading frames [17],
while transcripts of influenza virus gene segments 7 and 8
are spliced within the nucleus for production of two dif-
ferent sizes of mRNAs sharing the same 5'-proximal AUG
initial codon [16]. The P gene of Sendai virus is reported
to be transcribed into two polycistronic mRNAs, P/C and
V/C, which are translated to synthesis the P, C, C', Y1, and
Y2 proteins from independent start sites in two overlap-
ping reading frames [23-25].
Within the Paramyxoviridae, Newcastle disease virus pos-
sesses a polycistronic phosphoprotein (P) gene. Transcrip-
tional modification of the NDV P gene mRNA allows for
potential expression of two smaller putative proteins, des-
ignated V and W [12], that appears to be a result of
polymerase stuttering at the editing site sequences
[13,14], leading to the insertion of non-template G nucle-
otides within the P gene [12]. Consequently, during trans-
lation there is a frame shift resulting in production of the
V or W protein, dependent on the number of G nucle-
otides inserted [12]. It was previously suggested that NDV
[26] potentially utilized an alternative in-frame AUG start
site for expression of an accessory protein similar to the
Sendai virus X protein [21] that was recently demon-
strated to not be utilized during infection of cells in cul-
ture [27].
Pneumonia virus of mice, human and bovine respiratory
syncytial viruses, and avian metapneumovirus also pos-
sess polycistronic gene(s) [28-30]. The M2 gene of all the
pneumoviruses contains two partially overlapping open
reading frames, with the 5'-proximal open reading frame
favored for utilization by the criteria of location and
sequence of its start site [28,29]. The P gene of the pneu-
monia virus of mice is the only known polycistronic pho-
phoprotein gene in the pneumoviruses, and utilizes
internal initiation of in-frame AUG initiation codons to
generate up to four additional carboxy co-terminal prod-
ucts [30].
In this present study, we demonstrated that the nucleo-
protein gene of the avian metapneumovirus subtypes A
and C are putatively polycistronic. This may occur by uti-
lization of a second in-frame initiation site (AUG) for the
generation of a truncated nucleoprotein present among
infected Vero cells. Sequence analysis demonstrated the
presence of multiple putative initiation (AUG) start sites
along the N gene, however only one alternative start site
at nucleotide positions 212 and 410 for APV/C and APV/
A, respectively appear to be utilized to transcribe the N2
protein seen in infected cells.
The N protein of Pneumoviruses ranges in size from 42–
45 kD, based on SDS-PAGE relative mobility, and is
highly conserved among metapneumoviruses [7]. The N
Detection of avian metapneumovirus (aMPV) nucleoprotein  gene products among infected cells utilizing affinity purified  peptide antibodies Figure 3
Detection of avian metapneumovirus (aMPV) nucleoprotein 
gene products among infected cells utilizing affinity purified 
peptide antibodies. A. Antibody reacted against an N-termi-
nal portion of the nucleoprotein designed to detect all aMPV 
serotypes N1. Lane 1: molecular size markers; Lane 2: unin-
fected cell proteins; Lane 3: aMPV/A infected cell proteins; 
Lane 4: aMPV/B infected cell proteins; Lane 5: aMPV/C 
infected cell proteins. B. Antibody detection of a C-terminal 
portion of the aMPV/C nucleoprotein. Lane 1: uninfected cell 
proteins; Lane 2: aMPV/C infected cell proteins reacted with 
N1 peptide antibodies; Lane 3: aMPV/C infected cells reacted 
with aMPV/C-specific N2 peptide antibodies. C. Antibody 
detection of a C-terminal portion of the aMPV/A nucleopro-
tein. Lane 1: uninfected cell proteins; Lane 2: aMPV/A 
infected cell proteins reacted with N1 peptide antibodies; 
Lane 3: aMPV/A infected cell proteins reacted with N3 pep-
tide antibodies; Lane 4: aMPV/A infected cells reacted with 
N5 peptide antibodies.
A
B
CVirology Journal 2005, 2:31 http://www.virologyj.com/content/2/1/31
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protein, which protects the RNA genome from ribonucle-
ases, is associated with other viral proteins (P, M2, and L),
which together form the transcription complex. The
nucleocaspid is the template for transcription and replica-
tion; the RNA genome by itself cannot fulfill the role of
template. Pneumovirus infection in cells results in the
accumulation of the N protein in cytoplasmic inclusion
bodies that can be visualized by immunofluorescence
[31] or immunohistochemistry [7] as relatively large dots
that are usually close to the nucleus of infected cells.
Mapping of several paramyxovirus N proteins, including
Sendai and measles virus, indicated that the N protein has
two major domains; the amino terminal domain appears
to be required for nucleoprotein formation, containing
the domains necessary for RNA binding and N-N interac-
tions; while the carboxy-domain interacts with the phos-
phoprotein (P), particularly when it is part of the
polymerase complex [32,33]. In bovine respiratory syncy-
tial virus (bRSV), removal of the C-terminal 32 amino
acids of the N protein inhibits the interactions with the P
protein, whereas the removal of 32 amino acids from the
N-terminus has a minimal effect [32]. However, almost all
of the N from amino acids 2–391 is required to support
bRSV minigenome RNA synthesis [34]. The truncated N2
protein encompasses 328 amino acids (250 for aMPV/
Type A) of the carboxy terminus of the full-length N
protein, suggesting that N2 may not be involved in the
polymerase complex. However the domains responsible
for RNA binding of N-N and N-P binding remain intact,
suggesting that N2 may play an alternative role in cells
during viral infection.
Expression of N1 and N2 open reading frames of avian metapneumovirus type C in transfected eukaryotic cells by an expres- sion vector Figure 4
Expression of N1 and N2 open reading frames of avian metapneumovirus type C in transfected eukaryotic cells by an expres-
sion vector. Lane 1: molecular size markers; Lane 2: uninfected control cells; Lane 3. aMPV/C infected cells reacted with anti-
bodies to peptide N1. Lane 4: Cells transformed with aMPV/C-N gene complete ORF reacted with antibodies to peptide N1. 
Lane 5: Cells transformed with expression plasmid with truncated N2ORF reacted to antibodies to peptide N1; Lane 6: unin-
fected control cells; Lane 7: aMPV/C infected cells reacted to antibodies to peptide N4. Lane 8: Cells transformed with aMPV/
C-N gene complete ORF reacted with antibodies to peptide N2. Lane 9: Cells transformed with expression plasmid with trun-
cated N2ORF reacted to antibodies to peptide N2.Virology Journal 2005, 2:31 http://www.virologyj.com/content/2/1/31
Page 7 of 9
(page number not for citation purposes)
Methods
Cells and viruses
Vero cells were maintained as monolayer cultures in min-
imal essential media (MEM) supplemented to contain 8
% fetal bovine serum with 100 units/ml penicillin G,
0.025 µg/ml amphotericin B, and 100 units/ml strepto-
mycin. The aMPV/C/US/Co and aMPV/A/UK/3b isolates
were obtained from the National Veterinary Services Lab-
oratory (NVSL, APHIS, USDA, Ames, Iowa). Viruses were
propagated on 95% confluent Vero cell monolayers in
MEM supplemented to contain 2% FBS and antibiotics as
described previously [3]. Cells were infected at multiplic-
ity of infection of 10 (moi = 10), and virus was adsorbed
for 1 hour at 37°C. Media was added and cells were incu-
bated at 37°C, 5% CO2 for 72 hours or until 90% cyto-
pathic effect was observed by light microscopy. Cells were
scraped and harvested by centrifugation at 8000 × g.
Computer analyses, peptide synthesis and antibody 
production
The nucleoprotein (N) gene sequences of aMPV serotypes
A, B, and C (Genbank accession numbers: AAC55065,
AAG42499, and AAF05909) were analyzed in the
GeneWorks (Intelligentics, Mountain View, CA) and Mac
Vector (Accelrys, San Diego, CA) computer analysis pro-
grams to determine hydrophilicity, antigenicity, and iden-
tity of the deduced amino acid sequences. The sequences
were aligned for maximum similarity, and a consensus
sequence was determined using the most prevalent amino
acid for each residue. Five peptides with sequences: 1)
aMPV/N: DLSYKHAILKESQYTIKRDV; 2) aMPV/C-N2:
DKEARKTMASATKDNSGPIPQ; 3) aMPV/A-N3: ERT-
TREAMGAMVREKVQLTK; 4) aMPV/C-N4:
LNINEEGQNDY; and 5) aMPV/A-N5: LGGDDERSSKF
were chosen based on antigenicity and hydrophilicity to
be utilized for generation of aMPV peptide-based antibod-
ies. Peptides were synthesized by Research Genetics
(Huntsville, AL) according to the manufacturer's protocol.
Briefly, rabbit aMPV/N peptide antibodies were produced
by Research Genetics (Huntsville, AL) according to manu-
facturer's protocol. Two rabbits were injected with 0.1 mg
of KLH-conjugated peptide emulsified with Freud's com-
plete adjuvant and injected into four subcutaneous (SQ)
sites on day 1. On days 14, 42, and 56 rabbits were
injected again (boosters) with 0.1 mg of KLH-conjugated
peptide emulsified with Freud's complete adjuvant [35].
Sera were collected at days 0, 28, 56 and 70. Rabbit pre-
immune sera were used as negative controls for rabbit
assays.
SDS-PAGE and Western blot assay
Protein concentration of the supernatant fraction from
infected cells was measured for protein concentration by
Bradford's reagent (Bioworld, Dublin, OH) at 595 nm.
Infected supernatants were denatured in Laemmli's sam-
ple buffer (BioRad, Hercules, CA) and boiled for 5 min.
Denatured polypeptides (6 µg protein/lane) were sepa-
rated in a sodium dodecyl sulfate 4–20% polyacrylamide
Criterion (Biorad, Hercules, CA) gel gradient by electro-
phoresis (SDS-PAGE) at 120 V for 2 hours [36]. Polypep-
tides were transferred to nitrocellulose by applying a
constant voltage of 10 V for 1 hour on a Biorad (Hercules,
CA) Trans-Blot SD Semi-Dry Transfer cell [37]. Blots were
blocked with BLOTTO (20% dry milk in PBS) overnight at
4°C or for 1 hour at 37° and washed 3 X in phosphate
buffered saline (PBS). Affinity purified rabbit anti-peptide
antibody (diluted 1:100) was used as the source of the pri-
mary antibodies and incubated for 1 hour at 37°C fol-
lowed by 3 washes in PBS. Secondary antibody (α -rabbit
IgG-alkaline phosphatase, Sigma, The Woodlands, TX)
was added (1:500), incubated 1 hour at 37°C, washed 3 X
in PBS and developed using a alkaline phosphatase sub-
strate kit (Vector, Burlingame, CA).
Viral RNA Isolation accompanied by RT-PCR 
Amplification of aMPV/C/US/Co N1 and N2 ORF 
nucleotide sequences
Total RNA was isolated [38] from aMPV/C/US/Co-
infected Vero cell lysates using Qiagen's "RNeasy" kit
(Qiagne, Valencia, CA) according to the manufacturer's
protocol. RNA was analyzed for purity by agarose gel elec-
trophoresis in a 1.5% agarose gel, at 125 volts, and stained
with 10 µg/ml of ethidium bromide (Sigma, The Wood-
lands, TX). The aMPV N1 and N2 ORFs were reverse tran-
scribed using either the N1 (5'-
GAAATGTCTCTTCAGGGGATTCAG-3') and N1185C (5'-
AATCATTCTGGCCTTCCTCAT-3') primer pair or the
N212 (5'-ATGCAGTACGTGAGCACC-3') and N1185C
(5'-AATCATTCTGGCCTTCCTCAT-3') primer pair, fol-
lowed by 30 cycles of PCR [39]. RT-PCR amplification
products were analyzed by agarose gel electrophoresis and
the full length N1 ORF product and the N2 ORF product
were excised and purified before cloning into the expres-
sion vector pCR3.1-Topo (Invitrogen, Carlsbad, CA).
Molecular cloning, nucleotide sequencing, and eukaryotic 
expression of pCR3.1-N1ORF and pCR3.1-N2ORF
The N1 ORF and N2 ORF fragments of aMPV/C/US/Co
were cloned into the eukaryotic expression vector pCR3.1-
Topo (Invitrogen, Carlsbad, CA) according to the manu-
facturer's protocol. Plasmid DNA was isolated using Qia-
gen's miniprep kit (Qiagen, Valencia, CA). Double
stranded sequencing with Taq polymerase (Applied Bio-
systems Inc.) and fluorescent labeled dideoxynucleotides
was performed with an automated sequencer [40] on both
amplification products to verify identity and insure that
no changes in the ORFs had been made relative to the
original N gene. The pCR3.1-N1ORF and pCR3.1-N2ORF
vectors were transfected into Vero cells usingVirology Journal 2005, 2:31 http://www.virologyj.com/content/2/1/31
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lipofectamine (Invitrogen, Carlsbad, CA). Protein was
induced with IPTG (Sigma, The Woodlands, TX) at 24
hours post-transfected and total proteins were harvested
by scraping. An aliquot of uninduced and induced cells
were lysed in 2 X Laemmli's buffer, boiled for 5 minutes
and separated by SDS-PAGE on a 4–20% Criterion (Bio-
rad, Hercules, CA) gradient gel, followed by electroblot-
ting onto nitrocellulose as previously described.
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